{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:22Z","timestamp":1792602922775,"version":"4.5.0"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,10,22]]},"DOI":"10.1248\/bpb.b24-00305","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T22:10:57Z","timestamp":1729548657000},"page":"1668-1674","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of \u03b2-Blocker-Induced Bradyarrhythmia Using an Analysis of the Japanese Adverse Drug Event Report Database"],"prefix":"10.1248","volume":"47","author":[{"given":"Hiroyuki","family":"Motoishi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Meiji Pharmaceutical University"},{"name":"Department of Pharmacy, Soka Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ishii-Nozawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Meiji Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. <i>Br. J. Pharmacol.<\/i>, <b>144<\/b>, 317\u2013322 (2005).","DOI":"10.1038\/sj.bjp.0706048"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz K-N. Comparative pharmacology of human \u00cb-adrenergic receptor subtypes\u2014characterization of stably transfected receptors in CHO cells. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>369<\/b>, 151\u2013159 (2004).","DOI":"10.1007\/s00210-003-0860-y"},{"key":"3","unstructured":"3) Tilley DG, Houser SR, Koch WJ. Adrenergic Agonists and Antagonists. <i>Goodman &amp; Gilman\u2019s Pharmacological Basis of Therapeutics.<\/i> (Brunton LL, Knollmann BC eds.) 14th ed. McGraw-Hill, New York, pp. 251\u2013284 (2023)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Umemura S, Arima H, Arima S, <i>et al.<\/i> The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). <i>Hypertens. Res.<\/i>, <b>42<\/b>, 1235\u20131481 (2019).","DOI":"10.1038\/s41440-019-0284-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ono K, Iwasaki Y, Akao M, <i>et al.<\/i> JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. <i>Circ. J.<\/i>, <b>86<\/b>, 1790\u20131924 (2022).","DOI":"10.1253\/circj.CJ-22-0285"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. <i>Lancet<\/i>, <b>353<\/b>, 9\u201313 (1999).","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hoppe UC. Beta-blocker induced bradycardia\u2014should we pace? <i>Eur. J. Heart Fail.<\/i>, <b>6<\/b>, 449\u2013451 (2004).","DOI":"10.1016\/j.ejheart.2004.01.015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, Tonkin A, Perkovic V. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. <i>J. Am. Coll. Cardiol.<\/i>, <b>58<\/b>, 1152\u20131161 (2011).","DOI":"10.1016\/j.jacc.2011.04.041"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, Yusu S, Yoshino H. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. <i>Int. Heart J.<\/i>, <b>49<\/b>, 281\u2013293 (2008).","DOI":"10.1536\/ihj.49.281"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Fujita T. Signal detection of adverse drug reactions. <i>Jpn. J. Pharmacoepidemiol.<\/i>, <b>14<\/b>, 27\u201336 (2009).","DOI":"10.3820\/jjpe.14.27"},{"key":"11","unstructured":"11) Morikawa K. Analysis of drug safety information using large-scale adverse drug reactions database. Bull<i>. Natl. Inst. Health Sci.<\/i>, <b>129<\/b>, 1\u201326 (2011)."},{"key":"12","unstructured":"12) Ministry of Health, Labour and Welfare. \u201cThe Plan for Drug Safety Surveillance.\u201d: \u2039https:\/\/www.pmda.go.jp\/files\/000156059.pdf\u203a, accessed 11 September, 2022."},{"key":"13","unstructured":"13) Pharmaceutical and Medical Devices Agency. \u2039https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html\u203a, accessed July 20, 2022."},{"key":"14","unstructured":"14) Hirooka T, Yamada M. <i>Evaluation of risk of adverse reaction using PMDA \u2018Adverse Drug Reaction Database\u2019<\/i>. Database SAS user groups Ronbun-syu, pp. 263\u2013270 (2012). https:\/\/biostat.jp\/archive_teireikai_2.php"},{"key":"15","unstructured":"15) L\u00f3pez-Send\u00f3n J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur. Heart J.<\/i>, <b>25<\/b>, 1341\u20131362 (2004)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. <i>Am. J. Epidemiol.<\/i>, <b>151<\/b>, 531\u2013539 (2000).","DOI":"10.1093\/oxfordjournals.aje.a010240"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Chen JJ, Wang SJ, Tsai CA, Lin CJ. Selection of differentially expressed genes in microarray data analysis. <i>Pharmacogenomics J.<\/i>, <b>7<\/b>, 212\u2013220 (2007).","DOI":"10.1038\/sj.tpj.6500412"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset. <i>Life <\/i>(Basel), <b>12<\/b>, 1355 (2022).","DOI":"10.3390\/life12091355"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. <i>Drug Saf.<\/i>, <b>36<\/b>, 995\u20131006 (2013).","DOI":"10.1007\/s40264-013-0061-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yamada M, Handa J. Comparison of the onset time profile among the interferon formulations in adverse drug reaction of suicide- or diabetes-related. <i>Jpn. J. Pharmacoepidemiol<\/i>, <b>19<\/b>, 23\u201330 (2014).","DOI":"10.3820\/jjpe.19.23"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yamashita T, Inoue H. Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study. <i>J. Cardiol.<\/i>, <b>62<\/b>, 50\u201357 (2013).","DOI":"10.1016\/j.jjcc.2013.02.010"},{"key":"22","unstructured":"22) Sullivan RP, Houser SR, Koch WJ. Neurotransmission: the autonomic and somatic motor nervous systems. <i>Goodman &amp; Gilman\u2019s Pharmacological Basis of Therapeutics.<\/i> (Brunton LL, Knollmann BC ed.) 14th ed. McGraw-Hill, New York, pp. 173\u2013205 (2023)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) D\u00fcngen HD, Apostolovic S, Inkrot S, <i>et al.<\/i> Titration to target dose of bisoprolol <i>vs.<\/i> carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. <i>Eur. J. Heart Fail.<\/i>, <b>13<\/b>, 670\u2013680 (2011).","DOI":"10.1093\/eurjhf\/hfr020"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Tsutsui H, Isobe M, Ito H, <i>et al.<\/i> JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure. <i>Circ. J.<\/i>, <b>83<\/b>, 2084\u20132184 (2019).","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"25","unstructured":"25) Miyagishi A, Nakahara H, Hara Y. Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent. <i>Arch. Int. Pharmacodyn. Ther.<\/i>, <b>271<\/b>, 249\u2013262 (1984)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Maeda R. JADER from pharmacovigilance point of view. <i>Jpn. J. Pharmacoepidemiol.<\/i>, <b>19<\/b>, 51\u201356 (2014).","DOI":"10.3820\/jjpe.19.51"},{"key":"27","unstructured":"27) Post-marketing Data Science Advisory Group. Leap toward much better safety measures in Japan. <i>PMDRS<\/i>, <b>45<\/b>, 98\u2013105 (2014)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Pariente A, Avillach P, Salvo F, Thiessard F. Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, B\u00e9gaud B, Moore N. Effect of competition bias in signal generation: analysis of a research database of spontaneous reports in France. <i>Drug Saf.<\/i>, <b>35<\/b>, 855\u2013864 (2012).","DOI":"10.2165\/11631780-000000000-00000"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, B\u00e9gaud B, Moore N, Pariente A. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. <i>Pharmacoepidemiol. Drug Saf.<\/i>, <b>23<\/b>, 186\u2013194 (2014).","DOI":"10.1002\/pds.3454"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Sakai T. A Checklist of important points in research using JADER. <i>Jpn. J. Pharmacoepidemiol.<\/i>, <b>25<\/b>, 64\u201373 (2020).","DOI":"10.3820\/jjpe.25.64"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/10\/47_b24-00305\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T03:27:48Z","timestamp":1734751668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/10\/47_b24-00305\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00305","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"article-number":"b24-00305"}}